Trends in cancer incidence and deaths in the United Kingdom (UK) among individuals aged between 35 and 69 years.
ERS Genomics and medicines discovery catapult sign CRISPR/Cas9 license agreement
Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug discovery innovation